Follicular lymphoma (FL) is the second most common nonHodgkin lymphoma (NHL), accounting for 20-30% of all NHLs. In 2014, 18% of the registered lymphomas were FL in the Spanish Group of Lymphoma and Bone Marrow Transplant (RELINF) prospective registry. FL is an incurable disease, characterized by a pattern of multiple relapses, a decreasing duration of response, and a gradual acquisition of resistance to different drugs (Swerdlow et al, 2008; Kridel et al, 2012) . However, thanks to the introduction of new drugs, especially the inclusion of immunotherapy in standard induction and maintenance regimens, survival rates have increased up to 20 years (Herold et al, 2007; Marcus et al, 2008; Salles et al, 2011) . Unfortunately, some FLs will transform into aggressive lymphomas, most frequently diffuse large cell lymphoma (DLBCL), and also B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and Burkitt lymphoma (BCLU); this phenomenon has been associated with a poorer outcome (Montoto et al, 2007; Casulo et al, 2015) .
Transformed follicular lymphoma (tFL) has classically exhibited low cure rates with conventional therapies. It is considered to be one of the most unfavourable events of FL natural history.
Transformation may be suspected on the basis of clinical evidence, such as raised lactate dehydrogenase (LDH) level and other biological information about cellular turnover (hypercalcaemia), rapid nodal growth, decline in performance status, appearance of B symptoms and new extranodal sites of disease involvement (Bastion et al, 1997; Al-Tourah et al, 2008; Link et al, 2013) . In cases with clinical suspicion of tFL, 18 [F] fluorodeoxyglucose (FDG) positron emission tomography (PET) scans can help predict histological transformation (HT). Thus, standardized uptake values (SUVs) that vary between 10 and 17 are correlated with higher positive predictive values (PPVs) for predicting transformation (Schoder et al, 2005; Karam et al, 2006; Noy et al, 2009; Moskowitz et al, 2012) . However, histological assessment is the gold standard for the diagnosis of transformation (Casulo et al, 2015) . The incidence of tFL is not well established, mainly due to the different criteria used to define and classify transformation; in fact, most previous studies, including three of the four largest to date, combined clinical and histological criteria (Al-Tourah et al, 2008; Link et al, 2013; Casulo et al, 2015; Wagner-Johnston et al, 2015) . Few studies have been undertaken since the introduction of rituximab; among those done before the rituximab era, the rates of risk of transformation were 2-3% of FLs per year (Montoto et al, 2007) . Interestingly, the recent prospective National LymphoCare Study series (Wagner-Johnston et al, 2015) showed no significant variation in the risk of transformation after introduction of immunochemotherapy in FL treatment. Similar results were observed in the recent data from the PRIMA (Primary Rituximab and Maintenance) trial, which includes histological criteria, however these results were biased because this study included only patients with a partial (PR) or complete (CR) response after chemoimmunotherapy (Sarkozy et al, 2016) .
One of the aims of recent biological and clinical research has been to determine risk factors associated with transformation at FL diagnosis. High Follicular Lymphoma International Prognostic Index (FLIPI) (Solal-Celigny et al, 2004) has been associated with a higher risk of transformation in some studies, as have the individual factors comprising the index (Gine et al, 2006; Montoto et al, 2007; Wagner-Johnston et al, 2015) . Neither early initiation of treatment nor a watchful waiting policy have been associated with a different risk of HT (Gine et al, 2006) . There is no robust evidence of the protective use of either anthracyclines in induction or rituximab during induction or maintenance (Wagner-Johnston et al, 2015) . The impact of response to first line therapy has not been very well established.
Treatment at transformation is not yet well established (Montoto et al, 2007; Al-Tourah et al, 2008; Montoto & Fitzgibbon, 2011; Wagner-Johnston et al, 2015) . Until now, tFL patients have been excluded from most clinical trials, and the results of the most recent trials are not yet available. The role of autologous stem cell transplantation (ASCT) has been questioned in the rituximab era. Experts recommend the administration of consolidation regimens following salvage therapies at transformation in those patients who have been previously treated; in turn, patients who have not been treated at FL diagnosis would not have to undergo ASCT (Montoto, 2015) . For patients with tFL relapsing after ASCT, allogeneic transplantation may improve outcomes, although with considerable transplant-related morbidity (Ratanatharathorn et al, 1994; Doocey et al, 2005; Villa et al, 2013; Casulo et al, 2015) .
In this study, we have investigated the incidence of histologically confirmed transformation in a large consecutive series of 1734 patients from 18 centres between 2002 and 2012 in the Spanish Grupo Español de Linfoma y Transplante Aut ologo de M edula Osea (GELTAMO). Confirmed HT was mandatory for being considered in this study. We have analysed the clinical characteristics of patients at diagnosis and transformation in order to determine their effect on the cumulative incidence of HT (CI-HT) and survival following transformation (SFT). Finally, we have examined the role of ASCT when incorporated in transformation treatment.
Methods

Patients
Patients diagnosed with FL in 18 participating centres of the GELTAMO group were recruited in accordance with the following inclusion criteria: (i) grades 1 to 3A FL, (ii) consecutively diagnosed between 1 January 2002 and 31 December 2012. Patients with evidence of transformation at the time of initial FL diagnosis (e.g. composite histology FL + DLBCL), and FL grade 3B were excluded from the study. Patients were followed from diagnosis according to local policies. All surviving patients gave their consent to be included in the study, which was approved by the Ethical Committee of the University Hospital of Salamanca.
We recruited 1874 patient candidates for the analysis. However, 140 were excluded for various reasons, including an initial diagnosis of grade 3B FL (n = 58), de novo transformed lymphoma (composite FL + DLCBL, or discordant histology in different locations; n = 68), and data inconsistency or lack of follow-up (n = 14). The present study therefore examined 1734 patients.
The main clinico-biological variables at diagnosis and at the time of transformation were abstracted using a standard protocol. These included: date of birth, date of FL diagnosis, FL lymphoma histology, b2-microglobulin, FLIPI variables and score, first-line therapy, number of treatment lines received before transformation, treatment response, HT, Revised International Prognostic Index (R-IPI) (Sehn et al, 2007) variables and score at transformation, tFL histology, treatment strategy for tFL, ASCT and allogeneic SCT, death, cause of death and date of last follow-up.
Histological transformation
Transformation was defined on the basis solely of pathological criteria. Open biopsies were preferentially carried out, although core needle biopsies were acceptable. Biopsies were obtained when there was a clinical suspicion of tFL, accessible locations for biopsy, and physical status/comorbidities of the patient allowed it. Histological assessment of transformation confirmed one of the following diagnoses: DLBCL, BCLU, Burkitt lymphoma, composite lymphoma (FL + DLBCL) or FL grade 3B.
Statistical methods and definitions
CI-HT and differences in transformation incidence were calculated with respect to different variables. We considered death as a competing risk to calculate the CI-HT (Satagopan et al, 2004; Verduijn et al, 2011; Delgado et al, 2014 We used the Kaplan-Meier method to analyse survival. Differences between the curves were determined by the log-rank test. All probabilities were based on two-tailed distributions, with P-values < 0Á05 considered significant. Multivariate analysis consisted of developing Cox proportional hazards model (backward) including all variables with some indication of a significant association in the univariate test (P < 0Á1) and those potential confounders. To analyse the impact of response to therapy as a time-dependent variable on overall survival (OS), the Mantel and Byar method and time-dependent Cox analysis were used. We used SPSS v20.0 (IBM Corp., Armonk, NY, USA) and R software (available at www.r-project.org), as appropriate.
Response was assessed using computed tomography scan in most of the cases for re-evaluation, according to International Working Group criteria (Cheson et al, 1999 (Cheson et al, , 2007 . We estimated time to transformation (TTT) as the period from the date of initial FL diagnosis to date of transformation, death or last follow-up. OS was considered to be the time from initial diagnosis until death from any cause or last follow-up. SFT was calculated as the time of HT documentation until death from any cause or last follow-up.
Results
Baseline characteristics and treatment
The median age at diagnosis of the 1734 evaluable patients was 59 years (range, 16-97 years). Eight hundred patients (46%) were male. The histological distribution was: 634 FL grade 1 (37%); 609 grade 2 (35%); 270 grade 3A (16%) and 221 low-grade (1 or 2, 13%). The patients' main presenting features are summarized in Table I . After a median follow up of 6Á6 years, 368 patients had died, giving a 10-year OS of 72% [95% confidence interval (CI): 69-75].
The therapeutic approach is detailed in Table I . A watchful waiting policy was established for 139 patients (8%), whereas 1595 received treatment at diagnosis. Briefly, 1213 patients (70%) were treated with rituximab, alone (n = 85, 5%) or in combination (n = 1128, 65%); an anthracyclinecontaining regimen was used in 931 (54%) patients and purine-analogue combinations were provided for 270 (16%).
Response to first-line therapy could be assessed in 1571 patients (98Á5% of treated cases). Complete response (CR) or uncertain CR (uCR) was achieved in 1192 (75%) patients, while 281 (18%) had partial response (PR), and 98 (6%) showed no response, progression or early death (Table I) .
Histological transformation
One hundred six patients eventually developed biopsy-proven HT. Seven additional patients were excluded from the analysis because they lacked a precise histological assessment. The majority of cases (n = 90) corresponded to DLBCL. Considering the 106 patients who developed HT, median time to transformation was 2Á5 years after diagnosis (range, 0Á3-12Á5 years). The CI-HTs at 5 and 10 years were 5% and 8% respectively (Fig 1A) . Variables associated with 10-year CI-HT were FLIPI and response to first line therapy; CI-HT was 7%, 9% and 14% for low-, intermediate-and high-risk FLIPI, respectively (P < 0Á001) ( Table I) . Patients who reached CR after induction treatment showed lower 10-year CI-HT than partial responders or those who were refractory (6%, 11% and 38%, respectively; P < 0Á001) ( Table I , Fig 1C) . The watchful waiting policy was not associated with a higher 10-year CI-HT (15% vs. 9% for treated patients, P = 0Á19, Fig 1B) . No specific modality of treatment, including the use of rituximab (7Á2% vs. 9Á2%, P = 0Á2) was significantly associated with 10-year CI-HT. A multivariate analysis was performed to identify the variables significantly associated with 10-year CI-HT, including FLIPI, and response to first-line treatment as a time-dependent variable. In the final model, which was based on 1483 cases, high-risk FLIPI [Hazard ratio (HR) 2Á6, 95% CI: 1Á5-4Á5] and absence of response to front-line therapy (HR 2Á9, 95% CI: 1Á3-6Á8) were of independent value in predicting HT (Table I) .
We conducted a sub-analysis in the cohort of patients with R-CHOP (cyclophosphamide, daunorubicin, vincristine and prednisolone plus rituximab). In the multivariate analysis, high-risk FLIPI and absence of response to front-line therapy were of independent value in predicting HT (Table SI) .
Patient characteristics at transformation, and response to treatment
A clinical picture of transformed cases included new rapid nodal growth (with a necrotic feature at biopsy) in 81 patients (76%), appearance of B symptoms in 49 (53%), involvement of extranodal sites in 56 (53%), and raised serum LDH in 66 patients (62%) (Table SII). Of the evaluable patients, 58 (66%) were in Ann Arbor stage IV and 50 (53%) had a poor R-IPI. The median number of treatment (A) The CI-HT at 5 and 10 years was 5% and 8%, respectively. (B) Watchful waiting policy (continuous line) versus treatment (dotted line) was not associated with a significant higher incidence of transformation (P = 0Á19). (C) 10-year CI-HT for patients that were initially treated and achieved complete response (dashed line) was 6%, significantly lower than those that achieved only partial response (dotted line) (11%), and those non-responders (continuous line) (38% P < 0Á001).
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ª 2017 John Wiley & Sons Ltd lines before transformation was two (range 0-7), with 62% of patients having received a rituximab-containing regimen (Table SII) . Treatment after transformation of the 106 patients is summarized in Table SII . Overall, 89 patients (84%) received a rituximab-containing regimen, R-CHOP and R-ESHAP (etoposide, methylprednisolone, cyatarabine and cisplatin plus rituximab) being the most frequent (35% and 32%, respectively). Thirty-four patients (33%) reached CR, 14 (14%) achieved PR, whereas 54 (51%) experienced failure of salvage treatment, including five early deaths. Twenty-nine patients in overall response (CR + PR; OR) were submitted to further intensification of their treatment: 22 received autologous stem cell transplantation (ASCT), and seven received allogeneic SCT.
Survival following histological transformation and the role of ASCT
After a median follow-up after HT of 36 months (range, 1-129 months), 70 of 106 patients had died, with a 5-year SFT of 26% (95% CI: 20Á0-31Á2%, Fig 2A) . As indicated in Table II , patients with very good or good R-IPI at HT had significantly better SFT than those with poor risk R-IPI (5-year SFT 39% vs. 12%, respectively; P < 0Á001, Fig 2B) . Patients without prior treatment of their FL had a better 5-year SFT than those who were treated (44% vs. 24%; P = 0Á16), although the differences were not significant due to the small number of cases in the former group (n = 9; data not shown). No other patients' characteristics at HT predicted SFT.
Regarding treatment for HT, those patients who developed transformation without prior treatment and were treated with R-CHOP after transformation had a better 5-year SFT than those who were previously treated with R-CHOP (55% vs. 33%; P = 0Á04). Landmark analysis at six months after HT treatment for response was performed, excluding those cases that died before disease evaluation. Patients who achieved CR with salvage treatment had a more favourable outcome, with a better 5-year SFT than those who did not (47% vs. 5%, respectively; P < 0Á001, Fig 2C) . Finally, those patients receiving ASCT showed a better 5-year SFT than those without ASCT (75% vs. 25%; P = 0Á007; Table II) .
However, the groups of patients who received or did not receive ASCT were not comparable. Those patients undergoing ASCT were younger at transformation (58Á2 years vs. 67Á6 years; P = 0Á001) tended to have a better OR to HT treatment (88% vs. 28%; P < 0Á001) and a better R-IPI score (70% vs. 38%; P = 0Á012), than those patients who did not (Table SIII) .
In the multivariate analysis, no response to salvage therapy (HR 5Á3, 95% CI: 2Á4-12Á0), not receiving ASCT (HR 3Á9, 95% CI: 1Á5-10Á1) and poor risk R-IPI (HR 2Á2, 95% CI: 1Á1-4Á2) had an independent influence on 5-year SFT. International Prognosis Index (R-IPI) (dashed line) had a 5-year SFT of 12% as compared to those with very good or good R-IPI (continuous line, 39%, P < 0Á001). (C) Landmark 6 months. Patients who achieved complete or partial response with salvage therapy (continuous line) had increased 5-year SFT compared to those who did not achieve response (47% vs. 5%, P < 0Á001).
Impact of HT on overall survival
To assess the impact of HT as a time-dependent variable on the outcome of patients with FL we first used a Mantel and Byar test, showing that the appearance of HT significantly decreased patient OS (HR 14Á4, P < 0Á0001). The same result was obtained when HT was analysed as time-dependent variable in a Cox model. The main variables predicting poor OS in the whole series were older age, male sex, high serum b2-microglobulin and high-risk FLIPI (<0Á0001 in all the cases). A multivariate analysis was carried out, including the abovementioned variables plus response to first treatment (CR versus no CR) and HT as time-dependent variables. In the final model with 1337 patients, HT (HR 2Á9, P < 0Á0001) was, together with older age (HR 1Á1, P < 0Á0001), male sex (HR 1Á9, P < 0Á0001), high serum b2-microglobulin (HR 1Á4, P = 0Á022), high-risk FLIPI (HR 1Á9, P < 0Á0001) and CR achievement (HR 3Á2, P < 0Á0001), the most important variable for OS.
Discussion
Here we present the largest series to date (n = 1734) that has analysed transformation in follicular lymphoma where histological assessment was a mandatory criterion. We have used strict criteria to avoid the problems of confounding factors, such as the inclusion of FL grades 3B in the FL study cohort, and the classification of de novo transformed FLs in the transformed group of patients. We also analysed transformation in a cohort with the highest proportion of patients treated with rituximab alone or in combination (n = 1238, 71%). Although it is a retrospective study, all consecutive FL patients diagnosed between 2002 and 2012 were included in the study.
The CI-HTs were 5% and 8% at 5 and 10 years respectively; these rates are lower than previously reported (Bastion et al, 1997; Montoto et al, 2007; Al-Tourah et al, 2008; Wagner-Johnston et al, 2015) . These differences could be explained by the different criteria applied to patient recruitment and the definition of transformation. Furthermore, we have considered death as a competing risk, which might explain the differences in incidence rates (Delgado et al, 2014) . Although it has been suggested that patients with clinical suspicion of transformation are clinically comparable with those from patients with histologically confirmed transformation (Link et al, 2013) there is not enough evidence to consider them equally. Indeed, in some cases in which clinical suspicion would lead to the diagnosis of tFL, pathology reports have confirmed FL relapse (Gine et al, 2006) . Nevertheless, the exclusive use of the histological criterion may decrease the detection of cases of transformation, due to a possible lack of access to a biopsy or a lack of support of metabolic tests to guide the puncture. Thus, consensus about the definition of FL transformation needs to be reached. Meanwhile, in the present study, we have analysed rates and outcomes in a homogeneous cohort of patients with the certainty of having a histologically documented transformation.
The incidence of transformation was higher in patients with poor prognostic features, such as FLIPI, of FL at diagnosis, consistent with previous series including rituximabtreated patients (Link et al, 2013; Wagner-Johnston et al, 2015) . In our study a high percentage of patients reached CR or uCR after first-line therapy (74Á7%), which might be due to a high percentage of low-risk FLIPIs observed, given that only 9% of patients who achieved CR had high-risk FLIPIs. We want to highlight the description for the first time of the impact of the quality of the response to first-line therapy in the rituximab era, in which those with PR, and especially refractory disease patients, had the highest risk of CI-HT in our series. In the recent report from the PRIMA trial, which includes also histological criteria, transformation was not influenced by status of disease at entry of the study or after maintenance; this discrepancy could be due to the fact that (Sarkozy et al, 2016) . Given that most cases with tFL are DLCBL histologically, we considered including the R-IPI (Sehn et al, 2007) rather than FLIPI as the prognosis index at transformation to assess outcomes of these patients. Five-year SFT was poor in the HT group, which was mainly influenced by R-IPI and the response to salvage therapy. Notably, R-CHOP as a salvage therapy improves SFT in patients that did not receive it as a first-line therapy for FL, consistent with a recent report (Link et al, 2013) .
The role of ASCT in tFL is uncertain in the rituximab era, and has not been extensively analysed. Recent recommendations suggest an important role for ASCT in patients who had received treatment before HT (Montoto, 2015) . In our series, ASCT improved SFT in the global cohort of HT patients, as has been previously reported in both the prerituximab and rituximab eras (Montoto et al, 2007; BanHoefen et al, 2013; Link et al, 2013; Villa et al, 2013; Jackson et al, 2014; Wagner-Johnston et al, 2015) . However, the criteria for receiving ASCT might bias these studies, as these patients are younger and have better clinical conditions at HT diagnosis than those not selected for ASCT (Ban-Hoefen et al, 2013; Jackson et al, 2014) . Although there are too few cases to enable definitive conclusions to be drawn, we suggest that treatment strategy should be individualized for each patient in order to improve response rate. Prospective studies focusing on this should be performed in order to obtain reliable conclusions.
In conclusion, an international consensus on the definition of FL transformation must be reached if we are to reliably establish the CI-HT. Due to the relatively low incidence of this entity, retrospective and prospective international multicentre studies are needed to achieve this goal, and to define the outcomes using the current therapeutic strategies for tFL, including the role of ASCT and allogeneic SCT. New molecules that might be of use in this patient group should be tested specifically in future trials. Furthermore, given that patients at higher risk of transformation have higher FLIPIs, respond poorly and are more likely to be refractory to therapy, new strategies with new molecules in FL should be developed.
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